Showing results (2521-2530 of 2,573) with videos related to

Sort By:
Pageof 258
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 11, 2020
Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 TrialJames Chih-Hsin Yang, D Ross Camidge, Cheng-Ta Yang, et al.
JAMA Network Open|January 5, 2021
Characterization of Ebola Virus-Associated Eye DiseaseAllen O Eghrari, Rachel J Bishop, Robin D Ross, et al.
JTO Clinical and Research Reports|August 19, 2024
Characteristics of Long-Term Survivors With EGFR-Mutant Metastatic NSCLCWilliam Tompkins, Connor B Grady, Wei-Ting Hwang, et al.
Cancer Discovery|September 13, 2024
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound MutationsJessica J Lin, Joshua C Horan, Anupong Tangpeerachaikul, et al.
JTO Clinical and Research Reports|January 6, 2025
Changing Treatment and Metastatic Disease Patterns in Patients with EGFR Mutated NSCLC: An Academic Thoracic Medical Investigator's Consortium Registry AnalysisMargaret Stalker, Connor B Grady, Alex Watts, et al.
The New England Journal of Medicine|October 4, 2018
Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung CancerD Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn, et al.
Tomography (Ann Arbor, Mich.)|March 24, 2023
Animal Models and Their Role in Imaging-Assisted Co-Clinical TrialsDonna M Peehl, Cristian T Badea, Thomas L Chenevert, et al.
Lung Cancer (Amsterdam, Netherlands)|April 22, 2025
Osimertinib vs. Afatinib in 1L therapy of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC): A multi-institution, real-world survival analysisAdam Barsouk, Omar Elghawy, Alex Watts, et al.
Nature Genetics|January 19, 2002
Mutant chromatin remodeling protein SMARCAL1 causes Schimke immuno-osseous dysplasiaCornelius F Boerkoel, Hiroshi Takashima, Joy John, et al.
JAMA|May 22, 2014
Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugsMark G Kris, Bruce E Johnson, Lynne D Berry, et al.
Pageof 258